Related references
Note: Only part of the references are listed.Inhibitory effect of a TGFβ receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells
O. Shinto et al.
BRITISH JOURNAL OF CANCER (2010)
Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma
Y. Kato et al.
BRITISH JOURNAL OF CANCER (2010)
Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer
Yosuke Doi et al.
CANCER SCIENCE (2010)
Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma
Masakazu Yashiro et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation
Keren Borensztajn et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer
Peter Buechler et al.
NEOPLASIA (2007)
The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma
Yan Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
SB Wedam et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Expression of vascular endothelial growth factors A and C in human pancreatic cancer
Rui-Feng Tang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors
SP Cleary et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2004)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
Pancreatic cancer growth is inhibited by blockade of VEGF-RII
P Büchler et al.
SURGERY (2003)
Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy
S Ran et al.
NEOPLASIA (2003)
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:: a randomised controlled trial
JP Neoptolemos et al.
LANCET (2001)
A new mathematical model for relative quantification in real-time RT-PCR
MW Pfaffl
NUCLEIC ACIDS RESEARCH (2001)
Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor
PM Lacal et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2000)
De novo expression of vascular endothelial growth factor in human pancreatic cancer:: Evidence for an autocrine mitogenic loop
Z Von Marschall et al.
GASTROENTEROLOGY (2000)
Resected adenocarcinoma of the pancreas - 616 patients: Results, outcomes, and prognostic indicators
TA Sohn et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2000)
Share Paper
